IONS supply chain intelligence for Ionis Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Ionis Pharmaceuticals, Inc. (IONS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SWEDISH-ORPHAN-BIOVITRUM-AB | SWEDISH-ORPHAN-BIOVITRUM-AB | 92% | Under our agreements, we are responsible for supplying finished goods inventory to Sobi and Sobi is responsible for selling each medicine to the end customer. |
| PTC-THERAPEUTICS-INTERNATIONAL-LIMITED | PTC-THERAPEUTICS-INTERNATIONAL-LIMITED | 90% | Under the license agreement, we are eligible to receive royalties from PTC in the mid-20 percent range on net sales for each medicine. |
| MGX | Metagenomi Therapeutics, Inc. | 85% | Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: elopment, manufacture and commercialization of programs or product candidates.… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | ible to receive tiered royalties up to 30 percent on net sales. From inception through December 31, 2025, we have generated more than $125 million in payments under these collaborations. 16 PTC Thera… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: ible to receive tiered royalties up… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we u… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: rrowhead’s plozasiran product and the ’333 patent. 47. Arrowhead is entitled to a judicial declaration that the making, use, offer for sale, sale, or import i… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: Reciprocal relationship from IONS graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from IONS graph: Reciprocal relationship from BCYC g… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from IONS graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disru… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need… |
| PEPG | PepGen Inc. | 72% | Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise comp… |
| PRQR | ProQR Therapeutics N.V. | 72% | Reciprocal relationship from PRQR graph: upport of our third-party information technology providers, our ISM addresses areas such as: ● Assessment and treatment of cyber and information security risk… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acc… |
| RNA | Atrium Therapeutics, Inc. | 72% | Reciprocal relationship from RNA graph: Reciprocal relationship from IONS graph: Reciprocal relationship from RNA graph: Reciprocal relationship from IONS graph: Reciprocal relationship from RNA grap… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned product… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service providers to conduct our clinical studies f… |
| TMO | Thermo Fisher Scientific Inc. | 72% | vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we u… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 92% | We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, for the license we granted to AstraZeneca |
| AZN | AstraZeneca PLC | 92% | Reciprocal relationship from AZN graph: Reciprocal relationship from IONS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IONS graph: We determined that we had a vendor-cu… |
| ROCHE | ROCHE | 90% | We earned the following revenue from our relationship with Roche |
| ICON-CLINICAL-RESEARCH-LIMITED-MEDPACE-INC-PAREX | ICON-CLINICAL-RESEARCH-LIMITED-MEDPACE-INC-PAREX | 85% | inical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For exam… |
| SYNEOS-HEALTH-INC | SYNEOS-HEALTH-INC | 85% | inical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For exam… |
| TMO | Thermo Fisher Scientific Inc. | 85% | Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service providers to conduct our clinical studies f… |
| TMO | Thermo Fisher Scientific Inc. | 85% | vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we u… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | nt of certain development, regulatory and sales events. We will also reimburse Metagenomi for certain of its costs in conducting its research and drug discovery activities under the collaboration. Ot… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: nt of certain development, regulatory and sales events. We will also reimburse Metagenomi for certain of its costs in… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: rrowhead’s plozasiran product and the ’333 patent. 47. Arrowhead is entitled to a judicial declaration that the making, use, offer for sale, sale, or import i… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | h arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or medicines. We have incurred losses, and our business will suffer if we… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: Reciprocal relationship from IONS graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from IONS graph: Reciprocal relationship from BCYC g… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX grap… |
| MTVA | MetaVia Inc. | 72% | Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our sec… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acc… |
| AKCEA-THERAPEUTICS-INC | AKCEA-THERAPEUTICS-INC | 62% | cussed in this report on Form 10-K, including those identified in Item 1A, Risk Factors . Although our forward-looking statements reflect the good faith judgment of our management, these statements a… |
| CRS | Carpenter Technology Corporation | 62% | Reciprocal relationship from CRS graph: Reciprocal relationship from IONS graph: Reciprocal relationship from CRS graph: Reciprocal relationship from IONS graph: Reciprocal relationship from CRS grap… |
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 62% | payment of $ 10 million if Novartis advances a medicine under this collaboration. At the commencement of this collaboration, we identified one performance obligation, which was to perform R&D service… |
| HOFFMANN-LA-ROCHE-INC | HOFFMANN-LA-ROCHE-INC | 62% | payment of $ 10 million if Novartis advances a medicine under this collaboration. At the commencement of this collaboration, we identified one performance obligation, which was to perform R&D service… |
| ISIS-PHARMACEUTICALS-INC | ISIS-PHARMACEUTICALS-INC | 62% | cussed in this report on Form 10-K, including those identified in Item 1A, Risk Factors . Although our forward-looking statements reflect the good faith judgment of our management, these statements a… |
| OTSUKA-PHARMACEUTICAL-CO-LTD | OTSUKA-PHARMACEUTICAL-CO-LTD | 62% | e determined the transaction price to be the $ 60 million upfront payment we received in the fourth quarter 2023. We allocated the transaction price based on the estimated stand-alone selling price o… |
| PTC-THERAPEUTICS-INTERNATIONAL-LIMITED | PTC-THERAPEUTICS-INTERNATIONAL-LIMITED | 62% | liabilities $ 108,438 $ 147,894 3. Revenues During the years ended December 31, 2024 , 2023 and 2022, our revenues were comprised of the following (in thousands): Year Ended December 31, 2024 2023 20… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IONS-DEBT | Debt stack $1.8B | 90% | Market cache reports total debt of $1.8B. |
| IONS-DEBT-10330 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| IONS-DEBT-10329 | Warrants outstanding: 4250000 | 90% | xbrl warrant detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IONS-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 496 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer'] |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BTAI | BioXcel Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 1 | ['customer', 'supplier'] |
| RGNX | REGENXBIO Inc. | 100.00 | 2 |